Latest News for: duchenne muscular dystrophy

Edit

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (Form 8-K) (Keros Therapeutics Inc)

Public Technologies 20 Aug 2025
FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy ... the treatment of Duchenne muscular dystrophy ("DMD") ... About Duchenne Muscular Dystrophy (DMD).
Edit

Duchenne Muscular Dystrophy Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the ...

GetNews 15 Aug 2025
Inactive Products Duchenne Muscular Dystrophy Key Companies Duchenne Muscular Dystrophy Key Products Duchenne Muscular Dystrophy- Unmet Needs Duchenne Muscular Dystrophy- Market Drivers and Barriers ...
Edit

Tennessee boy channels 'The Flash' in race to cure Duchenne muscular dystrophy

The Tennessean 05 Aug 2025
12-year-old Deklan Locke, who has Duchenne muscular dystrophy, uses a power wheelchair and raises awareness about the disease.Duchenne muscular dystrophy is a rare genetic disorder that causes muscle ...
Edit

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

Nasdaq Globe Newswire 04 Aug 2025
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - �� ... .
Edit

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (Form 8-K) (Dyne Therapeutics Inc)

Public Technologies 04 Aug 2025
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) ... About Duchenne Muscular Dystrophy (DMD) ... muscular dystrophy (FSHD) and Pompe disease.
Edit

Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy (Hansa Biopharma AB)

Public Technologies 01 Aug 2025
2025-08-01 21.15.00 CEST Hansa Biopharma AB - Inside information Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy.
Edit

MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy

Hastings Tribune 29 Jul 2025
European Medicines Agency recognizes potential of lead ...
Edit

MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy (MetrioPharm AG)

Public Technologies 29 Jul 2025
2025-Jul-29 edicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD) Designation is paving the way for safer long-term ...
Edit

Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances ...

Nasdaq Globe Newswire 28 Jul 2025
The Duchenne muscular dystrophy market is witnessing steady growth driven by advancements in gene therapies, exon-skipping drugs, and corticosteroid alternatives.
Edit

Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU

Nasdaq Globe Newswire 25 Jul 2025
... for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).
Edit

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Business Wire 23 Jul 2025
... Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
Edit

Duchenne Muscular Dystrophy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Santhera ...

GetNews 16 Jul 2025
DelveInsight’s, "Duchenne Muscular Dystrophy - Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape.
Edit

CAP-1002: Capricor Therapeutics received Complete Response Letter from the U.S. FDA for Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy (Nippon Shinyaku Co Ltd)

Public Technologies 14 Jul 2025
) ... (Headquarters ... (Headquarters ... Food and Drug Administration (FDA) for its Biologics License Application (BLA) filing for CAP-1002 (also referred to as deramiocel) for the expected indication of Duchenne Muscular Dystrophy (DMD) cardiomyopathy ... Ltd.
Edit

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Nasdaq Globe Newswire 11 Jul 2025
... candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Edit

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy (Form 8-K) (Capricor Therapeutics Inc)

Public Technologies 11 Jul 2025
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy ● FDA issued Complete Response Letter ... Duchenne muscular dystrophy ... About Duchenne Muscular Dystrophy.

Article Search

tools
×
×
×
×